Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy Cowey CL; Rathmell WKCurr Oncol Rep 2009[Mar]; 11 (2): 94-101The therapeutic landscape for renal cell carcinoma (RCC) has changed drastically over the past several years with the emergence of molecularly targeted therapies. With previous prognostic and predictive tools based on studies of patients treated with cytokine therapies, confirmation of these prior methods and discovery of new markers in this new era of targeted therapy are of great importance. Alteration of the von Hippel-Lindau gene (VHL) by mutation, loss of heterozygosity, and promoter methylation has been found to be important to RCC pathogenesis. In this review, we discuss the potential role of VHL mutation as a prognostic and predictive marker for RCC.|*Mutation[MESH]|Biomarkers, Tumor[MESH]|Carcinoma, Renal Cell/drug therapy/*genetics[MESH]|Humans[MESH]|Kidney Neoplasms/drug therapy/*genetics[MESH]|Prognosis[MESH]|Vascular Endothelial Growth Factor A/antagonists & inhibitors[MESH]|Von Hippel-Lindau Tumor Suppressor Protein/*genetics[MESH] |
